Audrey Thomas‐Schoemann

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

Manuela Tiako Meyo, Anne Jouinot, Etienne Giroux‐Leprieur et al. · Cancers · 2020 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study

Pascaline Boudou‐Rouquette, Céline Narjoz, Jean Louis Golmard et al. · PLoS ONE · 2012 · 99 citations · Full text

Medicine, Oncology, Pharmacology +16

Arsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon Cancer

Audrey Thomas‐Schoemann, Frédéric Batteux, Céline Mongaret et al. · The Journal of Immunology · 2012 · 65 citations

Life Sciences, Immunology, Oncology +17

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients

Rafael Reis, Laurence Labat, Marie Allard et al. · Journal of Pharmaceutical and Biomedical Analysis · 2018 · 64 citations

Medicine, Oncology, Pharmacology +15

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients

Céline Narjoz, Anatole Cessot, Audrey Thomas‐Schoemann et al. · Investigational New Drugs · 2014 · 50 citations

Medicine, Pharmacokinetics, Pharmacology +16